These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26271457)

  • 1. The pleiotropic effects of metformin: time for prospective studies.
    Bromage DI; Yellon DM
    Cardiovasc Diabetol; 2015 Aug; 14():109. PubMed ID: 26271457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose lowering strategies and cardiovascular disease in type 2 diabetes - teachings from the TOSCA.IT study.
    Vaccaro O; Masulli M; Riccardi G
    Nutr Metab Cardiovasc Dis; 2018 Jul; 28(7):722-726. PubMed ID: 29804832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management.
    Luo F; Das A; Chen J; Wu P; Li X; Fang Z
    Cardiovasc Diabetol; 2019 Apr; 18(1):54. PubMed ID: 31029144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotective Effects of Metformin.
    Driver C; Bamitale KDS; Kazi A; Olla M; Nyane NA; Owira PMO
    J Cardiovasc Pharmacol; 2018 Aug; 72(2):121-127. PubMed ID: 29738369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy.
    van Stee MF; de Graaf AA; Groen AK
    Cardiovasc Diabetol; 2018 Jun; 17(1):94. PubMed ID: 29960584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycaemic therapy in type 2 diabetes. Part I. Metformin is the only glucose-lowering drug known to prevent complications of diabetes.
    Prescrire Int; 2015 Apr; 24(159):103-6. PubMed ID: 25941708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Steurer J
    Praxis (Bern 1994); 2016 Sep; 105(20):1221-1222. PubMed ID: 27705192
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction.
    Varjabedian L; Bourji M; Pourafkari L; Nader ND
    Am J Cardiovasc Drugs; 2018 Jun; 18(3):181-193. PubMed ID: 29478240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.
    Wurm R; Resl M; Neuhold S; Prager R; Brath H; Francesconi C; Vila G; Strunk G; Clodi M; Luger A; Pacher R; Hülsmann M
    Heart; 2016 Oct; 102(19):1544-51. PubMed ID: 27226327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis.
    Han Y; Xie H; Liu Y; Gao P; Yang X; Shen Z
    Cardiovasc Diabetol; 2019 Jul; 18(1):96. PubMed ID: 31362743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study.
    Bromage DI; Godec TR; Pujades-Rodriguez M; Gonzalez-Izquierdo A; Denaxas S; Hemingway H; Yellon DM
    Cardiovasc Diabetol; 2019 Dec; 18(1):168. PubMed ID: 31815634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the anti-diabetic actions of metformin: from the liver to the gut.
    Wu T; Horowitz M; Rayner CK
    Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):157-166. PubMed ID: 27983877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin: a multitasking medication.
    Bailey CJ
    Diab Vasc Dis Res; 2008 Sep; 5(3):156. PubMed ID: 18777487
    [No Abstract]   [Full Text] [Related]  

  • 15. Metformin therapy in diabetes: the role of cardioprotection.
    El Messaoudi S; Rongen GA; Riksen NP
    Curr Atheroscler Rep; 2013 Apr; 15(4):314. PubMed ID: 23423523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin and vascular protection: a diabetologist's view.
    Garber AJ
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S113-6. PubMed ID: 14502108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes: Time for reconciliation between cardiologists and diabetologists.
    Scheen AJ
    Nat Rev Cardiol; 2016 Sep; 13(9):509-10. PubMed ID: 27411401
    [No Abstract]   [Full Text] [Related]  

  • 19. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Anholm C; Kumarathurai P; Pedersen LR; Samkani A; Walzem RL; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Atherosclerosis; 2019 Sep; 288():60-66. PubMed ID: 31326727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin therapy and clinical uses.
    Scarpello JH; Howlett HC
    Diab Vasc Dis Res; 2008 Sep; 5(3):157-67. PubMed ID: 18777488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.